Monday, October 26, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· June 29, 2026

Corteva Announces Board of Directors for Advanced Seed and Genetics Spin-Off Vylor

View original at finance.yahoo.com

Corteva Announces Board of Directors for Advanced Seed and Genetics Spin-Off Vylor Karen Grimes to be Chair; separation on track for 4Q 2026 INDIANAPOLIS, June 29, 2026 /PRNewswire/ -- Corteva Inc…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Vylor will be a company dedicated to leveraging its expertise in advanced seed and genetics to help farmers feed and fuel the world, focused on accelerating the company's growth and impact and delivering results for shareholders.
60% confidence
Vylor's innovation engine will be anchored in the agriculture industry's most elite germplasm and transformative biotech, leveraging next generation scientific expertise in gene editing and molecular breeding.
60% confidence
A search is ongoing for at least one additional Vylor board member beyond the initial seven announced.
60% confidence
The Vylor separation remains on track for the fourth quarter of 2026.
60% confidence

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings

Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,994

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,994 facts checked against source5,500 source documents archived

Query this data → isubstrate.com